The global vertigo treatment market has been segmented, on the basis of treatment, into anticholinergics, antihistamines, benzodiazepines, and others. The anticholinergics segment is expected to hold the majority share of the market as they are vestibular suppressants and are most important in treating vertigo since these drugs do not cross the blood-brain barrier. The Benzodiazepines segment is expected to be the fastest growing as they are useful in controlling motion sickness and can also minimize anxiety and panic associated with vertigo. In terms of end user, the global vertigo treatment market has been segmented into hospitals and clinics. Hospitals take up the largest share.